FDA Approval of Keytruda® in Head and Neck Cancer Highlights Potential for Gedeptin® Combination Therapy
The FDA's approval of Keytruda® for head and neck cancer treatment underscores the therapeutic potential of combining it with GeoVax’s Gedeptin®, aiming to enhance tumor clearance and reduce relapse rates.
The recent U.S. Food and Drug Administration approval of Keytruda® (pembrolizumab) for resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) has significant implications for the treatment landscape, particularly for GeoVax Labs, Inc.'s Gedeptin® development program. This approval not only marks a pivotal advancement in curative-intent cancer therapy but also aligns with GeoVax's strategy to combine Gedeptin® with checkpoint inhibitors like pembrolizumab to improve outcomes for patients with HNSCC.
GeoVax is preparing to launch a Phase 2 clinical trial in 2026 to evaluate the efficacy of Gedeptin® in combination with a checkpoint inhibitor for patients scheduled for curative-intent surgery. The trial will focus on assessing pathologic response, recurrence rates, and immunologic changes, leveraging Gedeptin's tumor-targeted cytotoxicity to enhance the efficacy of immunotherapy. This approach is supported by recent findings published in the New England Journal of Medicine, which highlight the benefits of PD-1 inhibition in the curative setting for HNSCC and the need for optimized treatment strategies.
David Dodd, Chairman and CEO of GeoVax, emphasized the significance of this development, stating that the combination of Gedeptin therapy with pembrolizumab could enhance local tumor eradication and systemic anti-tumor immunity, potentially reducing recurrence. Dr. Kelly McKee, GeoVax’s Chief Medical Officer, added that Gedeptin's unique mechanism of action could prime anti-tumor immunity during the perioperative window, offering a promising avenue for advancing cancer treatment.